Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Company Overview

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts. The company has built in-house manufacturing capabilities through its SurePath platform, enabling scalable production of complex microbial therapies under stringent quality standards. Finch collaborates with academic centers and industry partners to accelerate clinical development and explore new therapeutic areas.

Under the leadership of co-founder and Chief Executive Officer Mark J. Smith, Finch has advanced multiple investigational products through early- and late-stage trials. The management team brings deep expertise in microbiology, clinical development and regulatory affairs, and is supported by a scientific advisory board of leading researchers in immunology, gastroenterology and microbial science. Finch’s clinical programs are primarily based in North America, with plans to initiate trials in additional regions as its pipeline progresses.

As a pioneer in the emerging field of microbiome therapeutics, Finch Therapeutics Group is dedicated to translating cutting-edge science into innovative treatments that address significant unmet medical needs. By harnessing the power of the human microbiome, Finch aims to deliver new therapeutic options that have the potential to transform the standard of care for patients suffering from chronic and recurrent diseases.

Key Stats

• Today's Range: $7.30 to $7.30
• 50-Day Range: $6.21 to $9.64
• 52-Week Range: $2.00 to $16.10
• Volume: N/A
• Average Volume: 5,025 shs
• Market Capitalization: $11.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/10/2021
• Today: 6/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FNCH
• CIK: 1733257
• Web: www.finchtherapeutics.com
• Phone: 617-229-6499
• Fax: N/A
• Employees: 190
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($8.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.14%
• Return on Assets: -26.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.87
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.25 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 1,606,000
• Free Float: 885,000
• Market Cap: $11.72 million
• Optionable: No Data
• Beta: 1.18